Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study.

Yu J, Xiong A, Wang Q, Chen J, Niu H, Zhou C, Tian P, Zhuang W, Li J, Wang J, Lu J, Gu K, Shi J, Guo J, Di Y, Lv D, Sun D, Cao L, Yang Z, Wu J, Miao L, Pan Y, Li C, Wu X, Yin J, Wang X, Sun M, He M, Cang S, Fang H, Chen P, Zhang M, Yang X, Zhao H, Feng J, Ma X, Hu S, Lu J, Zhao X, Zhuang Z, Sun Y, Sun X, Yu B, Zhu C, Chen J, Xu J, Wang K, Zhou C.

Open source

DOI: 10.1038/s41392-026-02904-0
Published: 2026-08-13
Container: Signal Transduct Target Ther
Publisher: Not recorded
Open access: yes

Credibility signals

uncertain Score 53/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
supportingDirectory of Open Access Journals: A matching record was returned by DOAJ. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41392-026-02904-0,
  title = {Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study.},
  author = {Yu J and  Xiong A and  Wang Q and  Chen J and  Niu H and  Zhou C and  Tian P and  Zhuang W and  Li J and  Wang J and  Lu J and  Gu K and  Shi J and  Guo J and  Di Y and  Lv D and  Sun D and  Cao L and  Yang Z and  Wu J and  Miao L and  Pan Y and  Li C and  Wu X and  Yin J and  Wang X and  Sun M and  He M and  Cang S and  Fang H and  Chen P and  Zhang M and  Yang X and  Zhao H and  Feng J and  Ma X and  Hu S and  Lu J and  Zhao X and  Zhuang Z and  Sun Y and  Sun X and  Yu B and  Zhu C and  Chen J and  Xu J and  Wang K and  Zhou C.},
  year = {2026},
  journal = {Signal Transduct Target Ther},
  doi = {10.1038/s41392-026-02904-0},
  url = {https://doi.org/10.1038/s41392-026-02904-0}
}

RIS

TY  - JOUR
TI  - Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study.
AU  - Yu J
AU  -  Xiong A
AU  -  Wang Q
AU  -  Chen J
AU  -  Niu H
AU  -  Zhou C
AU  -  Tian P
AU  -  Zhuang W
AU  -  Li J
AU  -  Wang J
AU  -  Lu J
AU  -  Gu K
AU  -  Shi J
AU  -  Guo J
AU  -  Di Y
AU  -  Lv D
AU  -  Sun D
AU  -  Cao L
AU  -  Yang Z
AU  -  Wu J
AU  -  Miao L
AU  -  Pan Y
AU  -  Li C
AU  -  Wu X
AU  -  Yin J
AU  -  Wang X
AU  -  Sun M
AU  -  He M
AU  -  Cang S
AU  -  Fang H
AU  -  Chen P
AU  -  Zhang M
AU  -  Yang X
AU  -  Zhao H
AU  -  Feng J
AU  -  Ma X
AU  -  Hu S
AU  -  Lu J
AU  -  Zhao X
AU  -  Zhuang Z
AU  -  Sun Y
AU  -  Sun X
AU  -  Yu B
AU  -  Zhu C
AU  -  Chen J
AU  -  Xu J
AU  -  Wang K
AU  -  Zhou C.
PY  - 2026
JO  - Signal Transduct Target Ther
DO  - 10.1038/s41392-026-02904-0
UR  - https://doi.org/10.1038/s41392-026-02904-0
ER  -

APA

J, Y., A, X., Q, W., J, C., H, N., C, Z., P, T., W, Z., J, L., J, W., J, L., K, G., J, S., J, G., Y, D., D, L., D, S., L, C., Z, Y., J, W., L, M., Y, P., C, L., X, W., J, Y., X, W., M, S., M, H., S, C., H, F., P, C., M, Z., X, Y., H, Z., J, F., X, M., S, H., J, L., X, Z., Z, Z., Y, S., X, S., B, Y., C, Z., J, C., J, X., K, W., & C., Z. (2026). Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study.. Signal Transduct Target Ther. https://doi.org/10.1038/s41392-026-02904-0

Source records

europe-pmc · retrieved 2026-09-27T05:03:28.788Z
doaj · retrieved 2026-09-27T05:03:28.804Z